Infant Bacterial Therapeutics AB (publ) (IBT-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) has a cash flow conversion efficiency ratio of -0.420x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-52.25 Million ≈ $-5.62 Million USD) by net assets (Skr124.36 Million ≈ $13.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Infant Bacterial Therapeutics AB (publ) balance sheet independence to measure how much of total assets are equity-financed.
Infant Bacterial Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IBT-B cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Infant Bacterial Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Infant Bacterial Therapeutics AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kutahya Seker Fabrikasi AS
IS:KTSKR
|
-0.005x |
|
Harn Len Corporation Bhd
KLSE:7501
|
0.080x |
|
Turbogen Chp
TA:TURB
|
1.208x |
|
SCOPE FLUIDICS SA ZY-10
F:S84
|
-0.072x |
|
Huadian Ener-B
SHG:900937
|
0.055x |
|
ProfilGruppen AB (publ)
ST:PROF-B
|
-0.017x |
|
Sao Mai Group Corp
VN:ASM
|
-0.024x |
|
FG Merger II Corp. Unit
NASDAQ:FGMCU
|
0.002x |
Annual Cash Flow Conversion Efficiency for Infant Bacterial Therapeutics AB (publ) (2014–2024)
The table below shows the annual cash flow conversion efficiency of Infant Bacterial Therapeutics AB (publ) from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Infant Bacterial Therapeutics AB (publ) stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr170.26 Million ≈ $18.32 Million |
Skr-113.13 Million ≈ $-12.17 Million |
-0.664x | -100.32% |
| 2023-12-31 | Skr305.15 Million ≈ $32.84 Million |
Skr-101.22 Million ≈ $-10.89 Million |
-0.332x | -28.24% |
| 2022-12-31 | Skr331.71 Million ≈ $35.70 Million |
Skr-85.80 Million ≈ $-9.23 Million |
-0.259x | -83.79% |
| 2021-12-31 | Skr395.25 Million ≈ $42.54 Million |
Skr-55.62 Million ≈ $-5.99 Million |
-0.141x | -6.08% |
| 2020-12-31 | Skr440.15 Million ≈ $47.37 Million |
Skr-58.39 Million ≈ $-6.28 Million |
-0.133x | -31.98% |
| 2019-12-31 | Skr510.40 Million ≈ $54.93 Million |
Skr-51.30 Million ≈ $-5.52 Million |
-0.101x | -18.03% |
| 2018-12-31 | Skr556.72 Million ≈ $59.91 Million |
Skr-47.41 Million ≈ $-5.10 Million |
-0.085x | +58.75% |
| 2017-12-31 | Skr168.37 Million ≈ $18.12 Million |
Skr-34.76 Million ≈ $-3.74 Million |
-0.206x | +45.34% |
| 2016-12-31 | Skr105.23 Million ≈ $11.32 Million |
Skr-39.75 Million ≈ $-4.28 Million |
-0.378x | -65.99% |
| 2015-12-31 | Skr74.81 Million ≈ $8.05 Million |
Skr-17.02 Million ≈ $-1.83 Million |
-0.228x | +33.45% |
| 2014-12-31 | Skr11.03 Million ≈ $1.19 Million |
Skr-3.77 Million ≈ $-405.93K |
-0.342x | -- |
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more